GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D…more
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D…more
Latest RNS from GSK plc
Analyst consensus: Hold
As of 21 Jul 2026, 22 analysts rate GSK plc a Hold, with 27% buy ratings and a mean price target of 2,139p (range 1,455p–2,825p), +14% vs the current price.
Valuation vs peers
Peer-relative fair value estimate: 2,433p against a current price of 1,893p (+29%), based on EV/EBITDA.